RxDoctor Payments Data

Allen Horne, MD

Family Medicine · McLean, VANPI 1225178296

Payments from drug & device makers

$2,385in general payments, 2019–2025

Across 103 payments — averaging $23.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$797
  • Pfizer$438
  • Boehringer Ingelheim$224
  • AbbVie$212
  • Amarin Pharma, Inc.$167
  • Biohaven Pharmaceutical Holding Company Ltd.$138
  • plus $409 from 11 others

What the payments were for

  • Food & beverage$2,385100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,385 in reported general payments places this provider in the 80th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$97,855
Medicare patients
396
Services billed
1,290

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban17$26,328
JardianceEmpagliflozin14$18,168
SynthroidLevothyroxine Sodium24$1,721
Atorvastatin Calcium155$1,448
Losartan Potassium71$998
Pantoprazole Sodium37$991
Rosuvastatin Calcium53$938
Simvastatin108$889
ValacyclovirValacyclovir Hcl18$880
Tamsulosin Hcl22$834
Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril22$813
Metoprolol Succinate48$753
Levothyroxine Sodium69$705
Amlodipine Besylate80$569
Metformin Hcl55$459

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$438$26,32817 claims
Boehringer IngelheimJardiance$224$18,16814 claims
AbbVieSynthroid$212$1,72124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in McLean

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →